Boston Scientific Corp (BSX)
Cash ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 865,000 | 952,000 | 426,000 | 570,000 | 928,000 | 338,000 | 276,000 | 325,000 | 1,925,000 | 1,947,000 | 2,675,000 | 2,016,000 | 1,734,000 | 2,022,000 | 1,724,000 | 370,000 | 217,000 | 277,000 | 123,000 | 139,000 |
| Short-term investments | US$ in thousands | — | — | 4,000 | 4,000 | 2,000 | 3,000 | 5,000 | 8,000 | 10,000 | 4,000 | 176,000 | 213,000 | 414,000 | 0 | 0 | 0 | 1,000 | — | 1,000 | 1,000 |
| Total current liabilities | US$ in thousands | 4,933,000 | 4,579,000 | 4,562,000 | 4,083,000 | 3,803,000 | 3,549,000 | 3,883,000 | 4,275,000 | 4,274,000 | 4,022,000 | 4,073,000 | 3,393,000 | 3,681,000 | 3,302,000 | 3,108,000 | 3,976,000 | 4,866,000 | 4,254,000 | 4,850,000 | 4,479,000 |
| Cash ratio | 0.18 | 0.21 | 0.09 | 0.14 | 0.24 | 0.10 | 0.07 | 0.08 | 0.45 | 0.49 | 0.70 | 0.66 | 0.58 | 0.61 | 0.55 | 0.09 | 0.04 | 0.07 | 0.03 | 0.03 |
December 31, 2023 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($865,000K
+ $—K)
÷ $4,933,000K
= 0.18
The cash ratio of Boston Scientific Corp. has fluctuated over the past eight quarters, with values ranging from 0.30 to 0.47. The cash ratio measures a company's ability to cover its short-term liabilities with its available cash and cash equivalents.
The trend in the cash ratio indicates that Boston Scientific Corp. maintains a relatively stable level of cash compared to its current liabilities. A decrease in the cash ratio may indicate potential liquidity concerns, while an increase may reflect a strengthened liquidity position.
In Q4 2022, the cash ratio was the highest at 0.47, indicating a relatively strong ability to cover short-term obligations with its cash holdings. However, in Q2 2023, the cash ratio decreased to 0.30, signaling a potential reduction in liquidity compared to the previous quarters.
Overall, while the company's cash ratio has shown fluctuations, it is crucial to monitor this ratio over time to assess Boston Scientific Corp.'s liquidity position and ability to meet its short-term financial obligations.
Peer comparison
Dec 31, 2023